[go: up one dir, main page]

MX2020003868A - Compuesto heterociclico como inhibidor de proteina quinasa. - Google Patents

Compuesto heterociclico como inhibidor de proteina quinasa.

Info

Publication number
MX2020003868A
MX2020003868A MX2020003868A MX2020003868A MX2020003868A MX 2020003868 A MX2020003868 A MX 2020003868A MX 2020003868 A MX2020003868 A MX 2020003868A MX 2020003868 A MX2020003868 A MX 2020003868A MX 2020003868 A MX2020003868 A MX 2020003868A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitor
heterocyclic compound
stereoisomer
pharmaceutically acceptable
Prior art date
Application number
MX2020003868A
Other languages
English (en)
Inventor
Dongkyu Kim
Ha Na Yu
Hyuk Woo Lee
Mi Kyung Ji
Seung Chan Kim
Soo Yeon Jung
Ji Yeon Park
Ye Lim Lee
Ho Youl Lee
So Young Ki
Myeongjoong Kim
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of MX2020003868A publication Critical patent/MX2020003868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un nuevo compuesto que tiene una actividad de inhibición de la proteína quinasa, un estereoisómero del mismo o una sal farmacéuticamente aceptable del mismo. El compuesto, el estereoisómero del mismo o la sal farmacéuticamente aceptable del mismo de acuerdo con la presente invención muestran una actividad de inhibición de la proteína quinasa, por lo que son eficaces para prevenir o tratar enfermedades relacionadas con la proteína quinasa, tales como cáncer, enfermedad autoinmune, enfermedad neurológica, enfermedad metabólica, infección o similar.
MX2020003868A 2017-10-18 2018-10-17 Compuesto heterociclico como inhibidor de proteina quinasa. MX2020003868A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170135515A KR20190043437A (ko) 2017-10-18 2017-10-18 단백질 키나제 억제제로서의 헤테로고리 화합물
PCT/KR2018/012270 WO2019078619A1 (en) 2017-10-18 2018-10-17 HETEROCYCLIC COMPOUND FOR USE AS A PROTEIN KINASE INHIBITOR

Publications (1)

Publication Number Publication Date
MX2020003868A true MX2020003868A (es) 2020-08-17

Family

ID=66174034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003868A MX2020003868A (es) 2017-10-18 2018-10-17 Compuesto heterociclico como inhibidor de proteina quinasa.

Country Status (10)

Country Link
US (1) US11524968B2 (es)
EP (1) EP3697787A4 (es)
JP (1) JP7112488B2 (es)
KR (1) KR20190043437A (es)
CN (1) CN111372931B (es)
AU (1) AU2018353759B2 (es)
CA (1) CA3082156C (es)
JO (1) JOP20180094A1 (es)
MX (1) MX2020003868A (es)
WO (1) WO2019078619A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
CN111479810B (zh) * 2018-01-31 2022-11-22 珠海联邦制药股份有限公司 Jak抑制剂及其应用
SI3860998T1 (sl) 2018-10-05 2024-06-28 Annapurna Bio Inc. Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CN112654605B (zh) * 2019-08-09 2022-11-22 中国医药研究开发中心有限公司 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
AU2020386639A1 (en) * 2019-11-22 2022-06-02 Shangpharma Innovation Inc. Caspase 6 inhibitors and uses thereof
CN113372351A (zh) * 2020-03-10 2021-09-10 明慧医药（杭州）有限公司 一类jak激酶抑制剂及其制备和应用
AU2021238799A1 (en) * 2020-03-17 2022-09-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof
TW202245774A (zh) * 2021-02-05 2022-12-01 大陸商上海齊魯製藥研究中心有限公司 嘧啶或吡啶並雜環類腺苷受體抑制劑及其製備方法和用途
WO2022197104A1 (ko) 2021-03-16 2022-09-22 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물의 결정형
CN117157293A (zh) * 2021-03-16 2023-12-01 怡诺安有限公司 作为蛋白激酶抑制剂的杂环化合物的新型盐及其用途
JP2024511349A (ja) * 2021-03-16 2024-03-13 エイチケー イノ．エヌ コーポレーション タンパク質キナーゼ阻害剤としてのヘテロ環化合物の新規塩およびこれらの用途
WO2024006493A1 (en) * 2022-07-01 2024-01-04 Biogen Ma Inc. Tyk2 inhibitors
CN121013710A (zh) * 2023-03-15 2025-11-25 怡诺安有限公司 包括激酶抑制剂的局部医药制品

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
CA2404594C (en) 2000-03-31 2010-12-21 Mitsubishi Pharma Corporation Agent for prophylaxis and treatment of renal disease
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
ATE319713T1 (de) 2000-10-03 2006-03-15 Bristol Myers Squibb Co Amino- substituierte tetracyclische verbindungen die als entzündungshemmende mittel nützlich sind, und diese enthaltende arzneimittel.
GB0100622D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
CA2440842A1 (en) 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
AU2003235741B8 (en) * 2002-01-07 2009-01-15 Eisai R&D Management Co., Ltd. Deazapurines and uses thereof
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
EP2308879A1 (en) 2004-04-02 2011-04-13 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
MX2007001399A (es) 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
AU2005323311A1 (en) 2004-11-23 2006-07-13 Venkateswara Rao Batchu Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
JP5002851B2 (ja) * 2005-01-20 2012-08-15 独立行政法人理化学研究所 イミダゾピリジン誘導体
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2436795T3 (es) 2005-06-14 2014-01-07 Merck Sharp & Dohme Corp. Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos
EP1741624A1 (en) 2005-07-06 2007-01-10 Aktiebolaget SKF Device and system for canting a keel arrangement about a longitudinal axis of a sailing vessel
DE102005049954A1 (de) 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
EP1968568A4 (en) * 2005-12-22 2011-04-13 Glaxosmithkline Llc HEMMER OF NUTS ACTIVITY
EP2102194A1 (en) 2006-12-08 2009-09-23 F. Hoffmann-Roche AG Substituted pyrimidines and their use as jnk modulators
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
PE20090054A1 (es) 2007-01-23 2009-01-26 Palau Pharma Sa Derivados de purina
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
WO2009027732A1 (en) * 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
WO2009049028A1 (en) * 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
CA2709883A1 (en) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
KR20100102651A (ko) 2008-01-22 2010-09-24 메르크 파텐트 게엠베하 단백질 키나제 억제제들 및 이의 이용
CA2718727A1 (en) 2008-03-25 2009-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2011518219A (ja) * 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
US9062056B2 (en) 2008-09-09 2015-06-23 Boehringer Ingelheim International Gmbh Aza-benzimidazolone Chymase inhibitors
CA2738348A1 (en) 2008-10-02 2010-04-08 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
SG172001A1 (en) 2008-12-08 2011-07-28 Sirtris Pharmaceuticals Inc Isoindolinone and related analogs as sirtuin modulators
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2767079A1 (en) 2009-07-08 2011-01-13 Leo Pharma A/S Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
KR20120059525A (ko) 2009-08-07 2012-06-08 메르크 파텐트 게엠베하 신규의 아자헤테로시클릭 화합물
WO2011060440A2 (en) 2009-11-16 2011-05-19 The Regents Of The University Of California Kinase inhibitors
US8440689B2 (en) 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
CA2799156A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
CA2813571A1 (en) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
NZ605889A (en) 2010-06-24 2014-10-31 Takeda Pharmaceutical Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
CN101885722B (zh) 2010-07-01 2013-07-24 中国科学院广州生物医药与健康研究院 杂环炔苯类化合物及其药用组合物和应用
US8975265B2 (en) 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
WO2012020787A1 (ja) 2010-08-11 2012-02-16 日本新薬株式会社 悪性リンパ腫治療剤
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US9388140B2 (en) 2011-03-31 2016-07-12 Bayer Intellectual Property Gmbh Substituted benzimidazoles
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CN102924445B (zh) 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
AU2012311504B2 (en) 2011-09-20 2016-03-24 Cellzome Limited Pyrazolo[4,3-C]pyridine derivatives as kinase inhibitors
CN103974956B (zh) 2011-11-29 2016-07-06 南京奥昭生物科技有限公司 作为hdac6抑制剂和用作抗肿瘤剂的杂环酰胺化合物
ES2516392T3 (es) 2012-01-19 2014-10-30 Taiho Pharmaceutical Co., Ltd. Compuesto de alquinilbenceno 3,5-disustituido y sal del mismo
HUE055502T2 (hu) 2012-07-11 2021-11-29 Blueprint Medicines Corp Fibroblaszt növekedési faktor receptor gátlók
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
EP2964221B1 (en) 2013-03-04 2017-12-06 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP2016512524A (ja) 2013-03-11 2016-04-28 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
WO2014159999A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
TW201533043A (zh) * 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
ES2761572T3 (es) 2013-07-11 2020-05-20 Acea Therapeutics Inc Derivados de pirimidina como inhibidores de quinasa
JP2016531113A (ja) 2013-07-25 2016-10-06 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 転写因子の阻害剤およびその使用
GB2518873A (en) 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
US9809568B2 (en) 2013-11-14 2017-11-07 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
UY35935A (es) 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
EP3110820B1 (en) 2014-02-28 2022-04-06 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
BR112016026518A2 (pt) 2014-05-14 2017-08-15 Univ Colorado Regents Ácidos hidroxâmicos heterocíclicos como inibidores da proteína desacetilase e inibidores duais de proteína desacetilase-proteína cinase e métodos de uso dos mesmos
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
EP3154547B1 (en) 2014-06-13 2023-06-07 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
AU2015291522B2 (en) 2014-07-17 2018-12-06 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
EP3290418B1 (en) 2015-04-29 2019-05-15 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase (jak) inhibitors
US20180201614A1 (en) 2015-05-12 2018-07-19 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
CN106478651B (zh) * 2015-08-31 2019-07-09 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
RU2760359C2 (ru) 2015-09-25 2021-11-24 Дизал (Цзянсу) Фармасьютикалз Ко., Лимитед Соединения и способы для ингибирования JAK
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
JP6888006B2 (ja) 2015-10-29 2021-06-16 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ１およびｍｎｋ２を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物
US20180312493A1 (en) 2015-11-04 2018-11-01 Simon Fraser University Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor
US11214565B2 (en) * 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
WO2017098467A1 (en) * 2015-12-09 2017-06-15 Jawaharlal Nehru Centre For Advanced Scientific Research Method for modulating autophagy and applications thereof
CA3016196A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
US11129808B2 (en) * 2016-03-15 2021-09-28 University Of South Florida PKC-delta-I inhibitor formulations and uses thereof
JP6943876B2 (ja) 2016-04-15 2021-10-06 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ Ｒｅｔキナーゼ阻害剤としての複素環化合物
CN110325533B (zh) 2016-09-16 2025-11-04 生命医药有限责任公司 Menin-mll相互作用的抑制剂
WO2018106459A1 (en) 2016-12-07 2018-06-14 New Era Pharma, Inc. Compounds and pharmaceutical compositions for modulating sgk activity, and methods thereof
EA201991528A1 (ru) 2016-12-22 2020-01-16 Эмджен Инк. БЕНЗИЗОТИАЗОЛЬНЫЕ, ИЗОТИАЗОЛО[3,4-b]ПИРИДИНОВЫЕ, ХИНАЗОЛИНОВЫЕ, ФТАЛАЗИНОВЫЕ, ПИРИДО[2,3-d]ПИРИДАЗИНОВЫЕ И ПИРИДО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ G12C KRAS ДЛЯ ЛЕЧЕНИЯ РАКА ЛЕГКОГО, РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ ИЛИ КОЛОРЕКТАЛЬНОГО РАКА
PE20191744A1 (es) 2017-01-30 2019-12-12 Chiesi Farm Spa Derivados de tirosinamida como inhibidores de rho-quinasa
IL317124A (en) * 2017-02-22 2025-01-01 Hadasit Med Res Service Compounds for the treatment of glycogen storage diseases
CN109384782A (zh) 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
MA49858A (fr) 2017-08-09 2021-04-28 Denali Therapeutics Inc Composés, compositions et procédés
SG11202002767RA (en) 2017-09-28 2020-04-29 Shanghai Haiyan Pharmaceutical Technology Co Ltd 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
CN111194319A (zh) 2017-10-19 2020-05-22 拜耳动物保健有限责任公司 稠合的杂芳族吡咯烷酮类化合物用于治疗和预防动物中的疾病的用途
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2019118909A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CN108084153A (zh) 2017-12-20 2018-05-29 广东赛烽医药科技有限公司 吡啶基硫代乙酸化合物、组合物及其应用
CA3088025A1 (en) 2018-02-06 2019-08-15 Ontario Institute For Cancer Research (Oicr) Inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof
US10947227B2 (en) 2018-05-25 2021-03-16 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
US11021482B2 (en) 2018-08-10 2021-06-01 Adaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors
JOP20190198A1 (ar) 2018-08-28 2020-02-28 Hk Inno N Corp تركيبة صيدلانية تشتمل على عامل مضاد للصفيحات ومثبط إفراز حمض معدي
JOP20190201A1 (ar) 2018-08-29 2020-02-29 Hk Inno N Corp تركيبة لاستئصال الملوية البوابية
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
US20210171544A1 (en) 2021-06-10
KR20190043437A (ko) 2019-04-26
CA3082156C (en) 2023-03-14
RU2020115890A3 (es) 2021-11-18
WO2019078619A1 (en) 2019-04-25
CA3082156A1 (en) 2019-04-24
AU2018353759A1 (en) 2020-06-04
EP3697787A4 (en) 2022-12-14
EP3697787A1 (en) 2020-08-26
BR112020007684A2 (pt) 2020-10-13
JOP20180094A1 (ar) 2019-04-18
JP7112488B2 (ja) 2022-08-03
CN111372931B (zh) 2023-03-24
RU2020115890A (ru) 2021-11-18
CN111372931A (zh) 2020-07-03
JP2021500339A (ja) 2021-01-07
US11524968B2 (en) 2022-12-13
AU2018353759B2 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
MX2020003868A (es) Compuesto heterociclico como inhibidor de proteina quinasa.
DOP2019000201A (es) Compuestos inhibidores del vih
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
CO2019004034A2 (es) Compuesto de piridina
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
MX390503B (es) Compuesto de pirimidina fusionada o sal del mismo.
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
CL2017001209A1 (es) Inhibidor de cinasa aurora a
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX2017009449A (es) Inhibidor jak.
MX2016011072A (es) Derivado de pirazol amida.
WO2015109340A3 (en) Vista antagonist and methods of use
EA201990400A1 (ru) Соединения и композиции и их применение
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
ZA201901168B (en) Novel compounds for treating parasitic disease
MX2021005740A (es) Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX375924B (es) Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.